Tom Powles, Professor of urology cancer at the University of London and the Director of Barts Cancer Centre, shared a post on X:
“This is the 2nd negative triplet study in 1st line metastatic kidney cancer – COSMIC 313 (ipi/nivo +\- cabo) was the other. It means sequencing doublets rather than giving everything upfront will be the standard of care for some time to come. Personalised therapy remained elusive in kidney cancer.”
Other articles featuring Tom Powles on OncoDaily.